Advertisement

Topics

Dr. Nicholas Kitchin, a member of our Vaccine Clinical R&D group, discusses the difficult-to-treat C. difficile infection & the work we’re doing to hopefully address this global public health threat in the future. http://bit.ly/2HorlZF  #WeWontRest cc

13:21 EDT 17 May 2019 | Pfizer

Dr. Nicholas Kitchin, a member of our Vaccine Clinical R&D group, discusses the difficult-to-treat C. difficile infection & the work we’re doing to hopefully address this global public health threat in the future. http://bit.ly/2HorlZF  cc:

Original Article: Dr. Nicholas Kitchin, a member of our Vaccine Clinical R&D group, discusses the difficult-to-treat C. difficile infection & the work we’re doing to hopefully address this global public health threat in the future. http://bit.ly/2HorlZF  #WeWontRest cc

NEXT ARTICLE

More From BioPortfolio on "Dr. Nicholas Kitchin, a member of our Vaccine Clinical R&D group, discusses the difficult-to-treat C. difficile infection & the work we’re doing to hopefully address this global public health threat in the future. http://bit.ly/2HorlZF  #WeWontRest cc"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...